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Abstract 
Context. The complex of symptoms in pancreatic cancer is vague, which often delays presentation and diagnosis. 
Thrombophlebitis is an unusual presentation of pancreatic cancer, which appears more frequent in the cancer of the body and tail of 
the pancreas. 
Case report. We present a case of a 52-years-old woman who was admitted to the hospital for a superficial thrombophlebitis. 
At the abdomen ultrasound screening, multiple liver masses, relatively well defined, with a hypo-echoic center and a hyper-echoic 
periphery, were identified. The head of the pancreas was normal, the body and the tail could not be seen very well due to flatulence. 
After computed tomography, the diagnosis was “Pancreatic tumor with multiple hepatic metastases (stage IV)”. After the 
histopathological examination, 1,250mg/m2 of Gemcitabine was started on day 1 and 8 every 28 days, plus 100mg/day of Erlotinib 
(Tarceva), every day. At the end of the seventh month of treatment, the patient suffered an irreversible ischemic cardiac event. 
Conclusion. Superficial thrombophlebitis can be the initial manifestation of the pancreatic cancer. Gemcitabine and erlotinib 
is now a FDA approved regimen for patients with metastatic pancreatic cancer. While the search for the best gemcitabine based 
backbone for advanced pancreatic cancer continues, studies of anti-angiogenic agents alone or in combination with traditional 
chemotherapy, should be undertaken, as they may improve overall survival in this group of poor prognosis patients. 
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Introduction 
The pancreatic cancer is the fourth leading cause of 
cancer death in North America, with the average age at 
diagnosis 60-65 years old [1]. The symptom complex is 
vague, which often delays presentation and diagnosis. 
Thrombophlebitis is an unusual presentation of pancreatic 
cancer, which appears more frequently in the cancer of 
the body and tail of the pancreas. Thrombophlebitis tends 
to occur in patients with more histological differentiated 
cancers. This is a relatively rare (5-15% of total 
presentations) presentation of pancreatic cancer; 
however, it is nonspecific and tends to occur more often in 
advanced disease. 
There are few long-term survivors and poor 
response to combined modality treatment. The 5-year 
survival is under 2%. The majority (80%) of patients 
present with an unresectable disease [1]. The epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors 
may be beneficial combined with chemotherapy, in these 
patients. 
Case report 
A 52-year-old Caucasian woman was admitted to 
the Internal Medicine Department with a 1-week history of 
edema, erythema and pain of the left lower extremity, 
diagnosed as superficial thrombophlebitis. The physical 
exam was normal, except for the thrombophlebitis. She 
had no personal pathological history, only a brother with 
malignant lymphoma. At the ultrasound screening of the 
abdomen multiple liver masses were identified. They were 
relatively well defined, with a hypo-echoic center and a 
hyper-echoic periphery, the largest measuring 45mm. The 
head of the pancreas was normal, the body and the tail 
could not be seen very well due to flatulence. Routine 
blood chemistry including liver and pancreatic function 
tests and blood cell count were normal. Computed 
tomography scan revealed multiple low-density masses 
measuring between 20-47 mm in the liver; a low-density 
ill-defined mass of 27/23mm, in the pancreas, with 
involvement of the uncinate process (Fig. 1, 2, 3). The 
diagnosis was 
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“Pancreatic tumor with multiple hepatic metastases 
(stage IV)”. The patient was referred to the Oncology and 
then Surgery Department, where she underwent 
laparoscopy with biopsy of a secondary hepatic lesion. 
The histopathological and immunohistochemical result 
was "liver biopsy fragment with neoplastic infiltration of 
well-differentiated adenocarcinoma, citokeratin 7 and CA 
125 positive in tumor cells, citokeratin 20 and 19 negative 
in tumor cells, OCH1E5 positive in the normal 
hepatocytes, negative in tumor cells, CDX2 negative, 
synaptophysin negative, chromogranin negative" (Fig. 
4,5,6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Abdominal computed tomography scan with contrast 
during the arterial phase. Multiple low-density masses in the 
liver; ill defined,  low-density mass, in the pancreas. 
Fig. 4. Hepatic metastatic lesion biopsy. 
Immunohistochemistry, CK 7 (+), 4x. 
Fig. 2. Abdominal computed tomography scan with contrast 
during the arterial phase. Multiple round-oval hypodense 
structures, with hyperdense periphery, in the liver. 
Fig. 5. Hepatic metastatic lesion biopsy. There are some 
little malignant glands in the left quadrant - pancreatic 
adenocarcinoma metastasis. H&E stain, 4x. 
 
Fig. 3. Abdominal computed tomography scan with contrast 
during the arterial phase. Multiple low-density masses in the 
liver; ill defined, low-density mass, in the pancreas. 
Fig. 6. Hepatic metastatic lesion biopsy. There are some 
little malignant glands in the left quadrant - pancreatic 
adenocarcinoma metastasis. H&E stain, 10x. 
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Conclusion: the histopathological aspect correlated 
with the immunohistochemical tests supports the 
diagnosis of adenocarcinoma with the point of departure in 
the epithelium of biliopancreatic ducts. 
1,250mg/m2 of Gemcitabine was started on day 1 
and 8 every 28 days, plus 100mg/day of Erlotinib 
(Tarceva) every day. Erlotinib is a small-molecule tyrosine 
kinase inhibitor of epidermal growth factor receptor 
(EGFR). At the beginning of the treatment, the patient had 
Hb of 9.6g/dL, platelets of 280,000/mm3 and white blood 
cells of 7,000/mm3. The body surface was of 1.59 m2. 
The patient developed recurrent episodes of 
migratory superficial thrombophlebitis, treated with 
heparin, then oral anticoagulants during the whole course 
of the disease. 
After the second month of treatment, the patient 
became icteric, so she was administered 1,025U/L of 
gammaglutamiltranspeptidase and 311U/L of alkaline 
phosphatase. She underwent a palliative biliary drainage. 
After 3 weeks of Erlotinib therapy, she developed an 
acneiform eruption on the face and chest (anterior and 
posterior). A therapeutic protocol was applied for the side 
effects of tirosinkinasis inhibitors: 1,000mg/day of Azitrox 
for 7 days, local applications of 3% Boric acid solution and 
Zineryt solution for 7 days [2,3]. In the second phase the 
patient received Diprogenta cream for 10 days, then 
Ruboril for the inflammatory erythema. 
The patient became anemic and received 
transfusions of erythrocytes concentrate repeatedly. The 
white blood cells and platelets were normal. 
After 4 months of treatment, Gemcitabine was 
stopped because the medullar toxicity occurred and the 
patient was treated only with Tarceva. Her evolution was 
good, only with mild pain in the upper abdomen (the only 
analgesic needed was dihydrocodein). At the end of the 
seventh month of treatment, the patient suffered an 
irreversible ischemic cardiac event. 
Discussion  
Gemcitabine is the first line therapy for patients with 
metastatic pancreatic adenocarcinoma with a median 
overall survival of 5.65 months, progression free survival 
of 9 weeks and a clinical benefit response of 23.8% [4]. 
Our patient had prolonged survival of 27 weeks that may 
be attributable to the addition of erlotinib. Erlotinib 
(Tarceva) is a human epidermal growth factor receptor 
type 1/epidermal growth factor receptor (HER1/EGFR)  
 
tyrosine kinase inhibitor initially approved by the US Food 
and Drug Administration in the treatment of patients with 
locally advanced or metastatic cancer. Erlotinib is the only 
oral epidermal growth factor tyrosine kinase inhibitor that 
has been shown to prolong overall survival in patients with 
advanced pancreatic cancer, although the benefit appears 
to be modest. It was approved by the Food and Drug 
Administration (FDA) in 2005, in combination with 
gemcitabine in the treatment of patients with locally 
advanced, unresectable or metastatic pancreatic 
carcinoma, who have not received previous chemotherapy 
[5,6]. 
The most common adverse reactions in patients 
with pancreatic cancer receiving 100 mg of Tarceva plus 
Gemcitabine are fatigue, nausea, anorexia and diarrhea. 
Our patient developed only the acneiform rash. In terms of 
clinical predictors of response, the development of skin 
rash has been suggested as a surrogate marker of 
favorable response to EGFR inhibition. The characteristic 
of EGFR inhibitor rash is papulopustular, predominantly 
occurring on the face and upper torso within two weeks 
from the start of treatment. Although the etiology remains 
unclear, the rash is postulated to occur secondary to 
EGFR inhibition in the skin [2]. Optimal dosage of erlotinib 
in advanced pancreatic cancer patients also remains at 
question.  In vitro studies suggest that drug concentration 
directly correlates with degree of antitumor effect, 
however, underscoring the importance of adequate 
dosing. Furthermore, the higher the doses of EGFR 
inhibitor are, the greater the incidence of rash [3]. 
Regarding the data suggesting that rash may be a 
biomarker for the tumor’s response to EGFR inhibition, 
this dose-toxicity relationship suggests the need for future 
study of dose escalation for the development of the rash. 
It is unknown whether higher doses of erlotinib can induce 
rash in a greater proportion of patients, and whether this 
would result in improved clinical outcomes without 
unacceptable toxicity. Given that even mild-to-moderate 
skin rash can result in significant patient distress and 
impairment, the clinical benefit of anti-EGFR therapy must 
be carefully weighed against the toxicity of this common 
side effect. 
Clinical trials involving other tyrosine kinase 
inhibitors and anti-angiogenic agents in pancreatic cancer 
are currently ongoing. The results of these and other 
ongoing clinical trials will help us redefine this regimen 
and determine the optimum doses and cycle length, for 
the most favorable results with minimum toxicities. 
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